Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Editor's comment: The editorial committee of Diabetes Care had some ethical concerns about potentially leaving patients for up to 24 weeks with blood pressure between 140/90 and 200/110 mmHg. After careful consideration, we decided to publish this article for the following reasons. First, the s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes care 2005-08, Vol.28 (8), p.1862-1868
Hauptverfasser: Yasuda, Gen, Ando, Daisaku, Hirawa, Nobuhito, Umemura, Satoshi, Tochikubo, Osamu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1868
container_issue 8
container_start_page 1862
container_title Diabetes care
container_volume 28
creator Yasuda, Gen
Ando, Daisaku
Hirawa, Nobuhito
Umemura, Satoshi
Tochikubo, Osamu
description Editor's comment: The editorial committee of Diabetes Care had some ethical concerns about potentially leaving patients for up to 24 weeks with blood pressure between 140/90 and 200/110 mmHg. After careful consideration, we decided to publish this article for the following reasons. First, the scientific information was considered valid and important. Second, the study was passed by the institutional review board (IRB) of the investigators. The study was passed by their institution at a time when perhaps ethical guidelines were not as stringent. Third, in response to queries by the editorial committee, the investigators pointed out that other hypertension studies initiated at around that time also had similar protocols. The editorial committee then dealt with the general issue of different criteria utilized by different IRBs around the world. Although the editorial committee will continue to be sensitive to decisions by various IRBs, investigators should realize that the more recent, stricter guidelines will also be considered by the editorial committee should ethical concerns be raised in the review process. OBJECTIVE:--Few studies have assessed whether 24-h blood pressure control induced by antihypertensive agents improves macroalbuminuria in hypertensive type 2 diabetic patients with overt nephropathy. We evaluated the effects of losartan and amlodipine on 24-h blood pressure, autonomic nervous activity, and albuminuria in these patients. RESEARCH DESIGN AND METHODS--In this open-label, parallel-prospective, randomized study, 44 patients were treated with losartan and 43 with amlodipine for a 12-week titration phase and a maintenance phase for a maximum of 12 weeks. Twenty-four-hour blood pressure and urinary albumin excretion were measured before and during treatment. Simultaneously, power spectral analysis of heart rate was performed to evaluate low frequency (LF) and high frequency (HF) components and LF-to-HF ratios as an index of sympathovagal balance. RESULTS:--Losartan decreased (P < 0.001) mean blood pressure from 162/91 to 150/82 mmHg during daytime and from 146/82 to 137/74 mmHg during nighttime (systolic/diastolic). Amlodipine also decreased (P < 0.001) blood pressure from 159/90 to 147/82 mmHg during daytime and from 143/81 to 131/72 mmHg during nighttime. LF and HF components and nighttime-to-daytime ratios for the LF-to-HF ratios did not differ during treatment in two groups, showing no changes in the diurnal autonomic nervous rhythm. Losar
doi_str_mv 10.2337/diacare.28.8.1862
format Article
fullrecord <record><control><sourceid>gale_fao_a</sourceid><recordid>TN_cdi_fao_agris_US201400141245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A135126221</galeid><sourcerecordid>A135126221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-3c2101b4ca9ac24785335df00be7e8f2e16ec9fa96c7592c91aec51a689070873</originalsourceid><addsrcrecordid>eNptkt-K1DAUxoso7jr6AN5oEPRC6Jg_TZtejuvoCoO74A5eltP0dCZLm3STdnUexnc144woMoQQEn7f-Q45X5I8Z3TOhSjeNQY0eJxzNVdzpnL-IDlnpZCplJl6mJxTlpWpLEt-ljwJ4ZZSmmVKPU7OWE4zUfDsPPm5bFvUYyCuJSsXwI9gCdiGLPrONWYwFomzZO2NBb8ji66eemPJ8of2OBr3h62nDkYXgfedcw259hjC5JFE9HI3oB_RBnOP5CZeCCcfDNRRrsk1jAZttP9mxi25uo8k-YLD1rsBxu3uafKohS7gs-M5S9YflzcXl-nq6tPni8Uq1VLIMRWaM8rqTEMJmmeFkkLIpqW0xgJVy5HlqMsWylwXsuS6ZIBaMshVSQuqCjFL3hzqDt7dTRjGqjdBY9eBRTeFKle0yBmTEXz1H3jrJm9jbxXngmaMR-tZkh6gDXRYGdu60YPeoEUPnbPYmvi8YEIynnPOIj8_wcfVYG_0SQE7CLR3IXhsq8GbPs6nYrTaJ6M6JqPiqlLVPhlR8-LY-VT32PxVHKMQgddHAIKGrvVgtQn_cGX8rXzPvT1wW7PZfjfRpPk9TQwnXV8e4BZcBRsfC66_8phLGjfjmRS_AETE20o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223041253</pqid></control><display><type>article</type><title>Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yasuda, Gen ; Ando, Daisaku ; Hirawa, Nobuhito ; Umemura, Satoshi ; Tochikubo, Osamu</creator><creatorcontrib>Yasuda, Gen ; Ando, Daisaku ; Hirawa, Nobuhito ; Umemura, Satoshi ; Tochikubo, Osamu</creatorcontrib><description>Editor's comment: The editorial committee of Diabetes Care had some ethical concerns about potentially leaving patients for up to 24 weeks with blood pressure between 140/90 and 200/110 mmHg. After careful consideration, we decided to publish this article for the following reasons. First, the scientific information was considered valid and important. Second, the study was passed by the institutional review board (IRB) of the investigators. The study was passed by their institution at a time when perhaps ethical guidelines were not as stringent. Third, in response to queries by the editorial committee, the investigators pointed out that other hypertension studies initiated at around that time also had similar protocols. The editorial committee then dealt with the general issue of different criteria utilized by different IRBs around the world. Although the editorial committee will continue to be sensitive to decisions by various IRBs, investigators should realize that the more recent, stricter guidelines will also be considered by the editorial committee should ethical concerns be raised in the review process. OBJECTIVE:--Few studies have assessed whether 24-h blood pressure control induced by antihypertensive agents improves macroalbuminuria in hypertensive type 2 diabetic patients with overt nephropathy. We evaluated the effects of losartan and amlodipine on 24-h blood pressure, autonomic nervous activity, and albuminuria in these patients. RESEARCH DESIGN AND METHODS--In this open-label, parallel-prospective, randomized study, 44 patients were treated with losartan and 43 with amlodipine for a 12-week titration phase and a maintenance phase for a maximum of 12 weeks. Twenty-four-hour blood pressure and urinary albumin excretion were measured before and during treatment. Simultaneously, power spectral analysis of heart rate was performed to evaluate low frequency (LF) and high frequency (HF) components and LF-to-HF ratios as an index of sympathovagal balance. RESULTS:--Losartan decreased (P &lt; 0.001) mean blood pressure from 162/91 to 150/82 mmHg during daytime and from 146/82 to 137/74 mmHg during nighttime (systolic/diastolic). Amlodipine also decreased (P &lt; 0.001) blood pressure from 159/90 to 147/82 mmHg during daytime and from 143/81 to 131/72 mmHg during nighttime. LF and HF components and nighttime-to-daytime ratios for the LF-to-HF ratios did not differ during treatment in two groups, showing no changes in the diurnal autonomic nervous rhythm. Losartan decreased (P &lt; 0.001) 24-h urinary albumin excretion from 810 mg/day (95% CI 780-1,140) to 570 (510-910). Amlodipine, however, did not decrease (P = 0.893) albuminuria (790 mg/day [780-1,170] vs.790 [710-1,260]). CONCLUSIONS:--These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/diacare.28.8.1862</identifier><identifier>PMID: 16043724</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; albumins ; Albuminuria - urine ; Amlodipine ; Amlodipine - therapeutic use ; antihypertensive agents ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Blood pressure ; Blood Pressure - drug effects ; Blood Pressure Monitoring, Ambulatory ; Diabetes ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetes Mellitus, Type 2 - urine ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - drug therapy ; Diabetic Angiopathies - physiopathology ; Diabetic Angiopathies - urine ; diurnal variation ; Dosage and administration ; Drug therapy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; ethics ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; excretion ; Excretory system ; Female ; guidelines ; heart rate ; Heart Rate - drug effects ; Humans ; hypertension ; Hypertension - drug therapy ; Hypertension - physiopathology ; Hypertension - urine ; Kidney diseases ; Losartan ; Losartan - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; noninsulin-dependent diabetes mellitus ; patients ; Side effects ; spectral analysis ; titration ; Type 2 diabetes ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland ; Urine</subject><ispartof>Diabetes care, 2005-08, Vol.28 (8), p.1862-1868</ispartof><rights>2005 INIST-CNRS</rights><rights>COPYRIGHT 2005 American Diabetes Association</rights><rights>Copyright American Diabetes Association Aug 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-3c2101b4ca9ac24785335df00be7e8f2e16ec9fa96c7592c91aec51a689070873</citedby><cites>FETCH-LOGICAL-c535t-3c2101b4ca9ac24785335df00be7e8f2e16ec9fa96c7592c91aec51a689070873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16989064$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16043724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yasuda, Gen</creatorcontrib><creatorcontrib>Ando, Daisaku</creatorcontrib><creatorcontrib>Hirawa, Nobuhito</creatorcontrib><creatorcontrib>Umemura, Satoshi</creatorcontrib><creatorcontrib>Tochikubo, Osamu</creatorcontrib><title>Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Editor's comment: The editorial committee of Diabetes Care had some ethical concerns about potentially leaving patients for up to 24 weeks with blood pressure between 140/90 and 200/110 mmHg. After careful consideration, we decided to publish this article for the following reasons. First, the scientific information was considered valid and important. Second, the study was passed by the institutional review board (IRB) of the investigators. The study was passed by their institution at a time when perhaps ethical guidelines were not as stringent. Third, in response to queries by the editorial committee, the investigators pointed out that other hypertension studies initiated at around that time also had similar protocols. The editorial committee then dealt with the general issue of different criteria utilized by different IRBs around the world. Although the editorial committee will continue to be sensitive to decisions by various IRBs, investigators should realize that the more recent, stricter guidelines will also be considered by the editorial committee should ethical concerns be raised in the review process. OBJECTIVE:--Few studies have assessed whether 24-h blood pressure control induced by antihypertensive agents improves macroalbuminuria in hypertensive type 2 diabetic patients with overt nephropathy. We evaluated the effects of losartan and amlodipine on 24-h blood pressure, autonomic nervous activity, and albuminuria in these patients. RESEARCH DESIGN AND METHODS--In this open-label, parallel-prospective, randomized study, 44 patients were treated with losartan and 43 with amlodipine for a 12-week titration phase and a maintenance phase for a maximum of 12 weeks. Twenty-four-hour blood pressure and urinary albumin excretion were measured before and during treatment. Simultaneously, power spectral analysis of heart rate was performed to evaluate low frequency (LF) and high frequency (HF) components and LF-to-HF ratios as an index of sympathovagal balance. RESULTS:--Losartan decreased (P &lt; 0.001) mean blood pressure from 162/91 to 150/82 mmHg during daytime and from 146/82 to 137/74 mmHg during nighttime (systolic/diastolic). Amlodipine also decreased (P &lt; 0.001) blood pressure from 159/90 to 147/82 mmHg during daytime and from 143/81 to 131/72 mmHg during nighttime. LF and HF components and nighttime-to-daytime ratios for the LF-to-HF ratios did not differ during treatment in two groups, showing no changes in the diurnal autonomic nervous rhythm. Losartan decreased (P &lt; 0.001) 24-h urinary albumin excretion from 810 mg/day (95% CI 780-1,140) to 570 (510-910). Amlodipine, however, did not decrease (P = 0.893) albuminuria (790 mg/day [780-1,170] vs.790 [710-1,260]). CONCLUSIONS:--These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action.</description><subject>Adult</subject><subject>albumins</subject><subject>Albuminuria - urine</subject><subject>Amlodipine</subject><subject>Amlodipine - therapeutic use</subject><subject>antihypertensive agents</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure Monitoring, Ambulatory</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetes Mellitus, Type 2 - urine</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Angiopathies - drug therapy</subject><subject>Diabetic Angiopathies - physiopathology</subject><subject>Diabetic Angiopathies - urine</subject><subject>diurnal variation</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>ethics</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>excretion</subject><subject>Excretory system</subject><subject>Female</subject><subject>guidelines</subject><subject>heart rate</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Hypertension - urine</subject><subject>Kidney diseases</subject><subject>Losartan</subject><subject>Losartan - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>noninsulin-dependent diabetes mellitus</subject><subject>patients</subject><subject>Side effects</subject><subject>spectral analysis</subject><subject>titration</subject><subject>Type 2 diabetes</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><subject>Urine</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt-K1DAUxoso7jr6AN5oEPRC6Jg_TZtejuvoCoO74A5eltP0dCZLm3STdnUexnc144woMoQQEn7f-Q45X5I8Z3TOhSjeNQY0eJxzNVdzpnL-IDlnpZCplJl6mJxTlpWpLEt-ljwJ4ZZSmmVKPU7OWE4zUfDsPPm5bFvUYyCuJSsXwI9gCdiGLPrONWYwFomzZO2NBb8ji66eemPJ8of2OBr3h62nDkYXgfedcw259hjC5JFE9HI3oB_RBnOP5CZeCCcfDNRRrsk1jAZttP9mxi25uo8k-YLD1rsBxu3uafKohS7gs-M5S9YflzcXl-nq6tPni8Uq1VLIMRWaM8rqTEMJmmeFkkLIpqW0xgJVy5HlqMsWylwXsuS6ZIBaMshVSQuqCjFL3hzqDt7dTRjGqjdBY9eBRTeFKle0yBmTEXz1H3jrJm9jbxXngmaMR-tZkh6gDXRYGdu60YPeoEUPnbPYmvi8YEIynnPOIj8_wcfVYG_0SQE7CLR3IXhsq8GbPs6nYrTaJ6M6JqPiqlLVPhlR8-LY-VT32PxVHKMQgddHAIKGrvVgtQn_cGX8rXzPvT1wW7PZfjfRpPk9TQwnXV8e4BZcBRsfC66_8phLGjfjmRS_AETE20o</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Yasuda, Gen</creator><creator>Ando, Daisaku</creator><creator>Hirawa, Nobuhito</creator><creator>Umemura, Satoshi</creator><creator>Tochikubo, Osamu</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy</title><author>Yasuda, Gen ; Ando, Daisaku ; Hirawa, Nobuhito ; Umemura, Satoshi ; Tochikubo, Osamu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-3c2101b4ca9ac24785335df00be7e8f2e16ec9fa96c7592c91aec51a689070873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>albumins</topic><topic>Albuminuria - urine</topic><topic>Amlodipine</topic><topic>Amlodipine - therapeutic use</topic><topic>antihypertensive agents</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure Monitoring, Ambulatory</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetes Mellitus, Type 2 - urine</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Angiopathies - drug therapy</topic><topic>Diabetic Angiopathies - physiopathology</topic><topic>Diabetic Angiopathies - urine</topic><topic>diurnal variation</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>ethics</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>excretion</topic><topic>Excretory system</topic><topic>Female</topic><topic>guidelines</topic><topic>heart rate</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Hypertension - urine</topic><topic>Kidney diseases</topic><topic>Losartan</topic><topic>Losartan - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>noninsulin-dependent diabetes mellitus</topic><topic>patients</topic><topic>Side effects</topic><topic>spectral analysis</topic><topic>titration</topic><topic>Type 2 diabetes</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yasuda, Gen</creatorcontrib><creatorcontrib>Ando, Daisaku</creatorcontrib><creatorcontrib>Hirawa, Nobuhito</creatorcontrib><creatorcontrib>Umemura, Satoshi</creatorcontrib><creatorcontrib>Tochikubo, Osamu</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Agriculture Science Database</collection><collection>ProQuest Family Health</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yasuda, Gen</au><au>Ando, Daisaku</au><au>Hirawa, Nobuhito</au><au>Umemura, Satoshi</au><au>Tochikubo, Osamu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>28</volume><issue>8</issue><spage>1862</spage><epage>1868</epage><pages>1862-1868</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>Editor's comment: The editorial committee of Diabetes Care had some ethical concerns about potentially leaving patients for up to 24 weeks with blood pressure between 140/90 and 200/110 mmHg. After careful consideration, we decided to publish this article for the following reasons. First, the scientific information was considered valid and important. Second, the study was passed by the institutional review board (IRB) of the investigators. The study was passed by their institution at a time when perhaps ethical guidelines were not as stringent. Third, in response to queries by the editorial committee, the investigators pointed out that other hypertension studies initiated at around that time also had similar protocols. The editorial committee then dealt with the general issue of different criteria utilized by different IRBs around the world. Although the editorial committee will continue to be sensitive to decisions by various IRBs, investigators should realize that the more recent, stricter guidelines will also be considered by the editorial committee should ethical concerns be raised in the review process. OBJECTIVE:--Few studies have assessed whether 24-h blood pressure control induced by antihypertensive agents improves macroalbuminuria in hypertensive type 2 diabetic patients with overt nephropathy. We evaluated the effects of losartan and amlodipine on 24-h blood pressure, autonomic nervous activity, and albuminuria in these patients. RESEARCH DESIGN AND METHODS--In this open-label, parallel-prospective, randomized study, 44 patients were treated with losartan and 43 with amlodipine for a 12-week titration phase and a maintenance phase for a maximum of 12 weeks. Twenty-four-hour blood pressure and urinary albumin excretion were measured before and during treatment. Simultaneously, power spectral analysis of heart rate was performed to evaluate low frequency (LF) and high frequency (HF) components and LF-to-HF ratios as an index of sympathovagal balance. RESULTS:--Losartan decreased (P &lt; 0.001) mean blood pressure from 162/91 to 150/82 mmHg during daytime and from 146/82 to 137/74 mmHg during nighttime (systolic/diastolic). Amlodipine also decreased (P &lt; 0.001) blood pressure from 159/90 to 147/82 mmHg during daytime and from 143/81 to 131/72 mmHg during nighttime. LF and HF components and nighttime-to-daytime ratios for the LF-to-HF ratios did not differ during treatment in two groups, showing no changes in the diurnal autonomic nervous rhythm. Losartan decreased (P &lt; 0.001) 24-h urinary albumin excretion from 810 mg/day (95% CI 780-1,140) to 570 (510-910). Amlodipine, however, did not decrease (P = 0.893) albuminuria (790 mg/day [780-1,170] vs.790 [710-1,260]). CONCLUSIONS:--These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>16043724</pmid><doi>10.2337/diacare.28.8.1862</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-5992
ispartof Diabetes care, 2005-08, Vol.28 (8), p.1862-1868
issn 0149-5992
1935-5548
language eng
recordid cdi_fao_agris_US201400141245
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adult
albumins
Albuminuria - urine
Amlodipine
Amlodipine - therapeutic use
antihypertensive agents
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Blood pressure
Blood Pressure - drug effects
Blood Pressure Monitoring, Ambulatory
Diabetes
Diabetes Mellitus, Type 2 - physiopathology
Diabetes Mellitus, Type 2 - urine
Diabetes. Impaired glucose tolerance
Diabetic Angiopathies - drug therapy
Diabetic Angiopathies - physiopathology
Diabetic Angiopathies - urine
diurnal variation
Dosage and administration
Drug therapy
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
ethics
Etiopathogenesis. Screening. Investigations. Target tissue resistance
excretion
Excretory system
Female
guidelines
heart rate
Heart Rate - drug effects
Humans
hypertension
Hypertension - drug therapy
Hypertension - physiopathology
Hypertension - urine
Kidney diseases
Losartan
Losartan - therapeutic use
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
noninsulin-dependent diabetes mellitus
patients
Side effects
spectral analysis
titration
Type 2 diabetes
Urinary system involvement in other diseases. Miscellaneous
Urinary tract. Prostate gland
Urine
title Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A14%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_fao_a&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Losartan%20and%20Amlodipine%20on%20Urinary%20Albumin%20Excretion%20and%20Ambulatory%20Blood%20Pressure%20in%20Hypertensive%20Type%202%20Diabetic%20Patients%20With%20Overt%20Nephropathy&rft.jtitle=Diabetes%20care&rft.au=Yasuda,%20Gen&rft.date=2005-08-01&rft.volume=28&rft.issue=8&rft.spage=1862&rft.epage=1868&rft.pages=1862-1868&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/diacare.28.8.1862&rft_dat=%3Cgale_fao_a%3EA135126221%3C/gale_fao_a%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223041253&rft_id=info:pmid/16043724&rft_galeid=A135126221&rfr_iscdi=true